Why Is ArriVent BioPharma ($AVBP) Stock Down -54.18% Today? (Find out why any stock moved today on Tickeron.) Shares plunged 54.18% to $13.04, down $15.42 from the prior session's close of $28.46. The primary catalyst was the failure of the pivotal Phase 3 FURVENT trial of lead drug candidate firmonertinib to meet its primary endpoint. Firmonertinib did not show a statistically significant improvement in progression-free survival versus chemotherapy in first-line EGFR exon 20 insertion-mutant non-small cell lung cancer. Secondary endpoints showed some clinical benefit, and an immature overall-survival trend appeared favorable, offering partial mitigation. $ABEO $VIR $DNLI $TSHA $IMTX
published
Why Is ArriVent BioPharma ($AVBP) Stock Down -54.18% Today? (Find out why any stock moved today on Tickeron.) Shares plunged 54.18% to $13.04, down $15.42 from the prior session's close of $28.46. The primary catalyst was the failure of the pivotal Phase 3 FUR
$AVBP$ABEO$VIR$DNLI$TSHA$IMTX
Latest documented BWB result
$NVDA market result
Exit $NVDA with $3 profit per share
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.